Cargando…
Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592269/ https://www.ncbi.nlm.nih.gov/pubmed/36281159 http://dx.doi.org/10.1097/MD.0000000000031163 |
_version_ | 1784814886365167616 |
---|---|
author | Wang, Shengnan Miao, Shijian Qiu, Xiaoxia Wu, Jie Wang, Yuhuan |
author_facet | Wang, Shengnan Miao, Shijian Qiu, Xiaoxia Wu, Jie Wang, Yuhuan |
author_sort | Wang, Shengnan |
collection | PubMed |
description | Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We retrieved data of consecutive patients aged 2 to 17 years old with established CD who underwent SBCE from Janurary 2017 to April 2020 and had endoscopic remission on ileocolonoscopy. Sixty-eight patients were included in the analysis. There were 13 patients with a weighted pediatric CD activity index ≥ 12.5, 47 patients with FC ≥ 200 µg/g, and 45 patients with significant small bowel (SB) inflammation [Lewis score (LS) ≥ 135]. The LS correlated weakly with FC (R = 0.30, P < .05). The area under the curve of FC as a surrogate diagnostic test for LS ≥ 135 was 0.691, and the optimal FC cutoff values were 242 µg/g with the corresponding sensitivity and specificity of 78% and 65%, respectively. The area under the curve of FC for moderate-to-severe inflammatory activity in the SB was 0.718. In patients with FC level ≥ 670 µg/g, LS ≥ 790 was found in 33% (9/27) of patients, with the sensitivity and specificity of 69% and 67%, respectively. FC may be used to predict SB mucosal inflammation in pediatric patients with confirmed CD having endoscopic remission on ileocolonoscopy. |
format | Online Article Text |
id | pubmed-9592269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95922692022-10-25 Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease Wang, Shengnan Miao, Shijian Qiu, Xiaoxia Wu, Jie Wang, Yuhuan Medicine (Baltimore) Research Article Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We retrieved data of consecutive patients aged 2 to 17 years old with established CD who underwent SBCE from Janurary 2017 to April 2020 and had endoscopic remission on ileocolonoscopy. Sixty-eight patients were included in the analysis. There were 13 patients with a weighted pediatric CD activity index ≥ 12.5, 47 patients with FC ≥ 200 µg/g, and 45 patients with significant small bowel (SB) inflammation [Lewis score (LS) ≥ 135]. The LS correlated weakly with FC (R = 0.30, P < .05). The area under the curve of FC as a surrogate diagnostic test for LS ≥ 135 was 0.691, and the optimal FC cutoff values were 242 µg/g with the corresponding sensitivity and specificity of 78% and 65%, respectively. The area under the curve of FC for moderate-to-severe inflammatory activity in the SB was 0.718. In patients with FC level ≥ 670 µg/g, LS ≥ 790 was found in 33% (9/27) of patients, with the sensitivity and specificity of 69% and 67%, respectively. FC may be used to predict SB mucosal inflammation in pediatric patients with confirmed CD having endoscopic remission on ileocolonoscopy. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592269/ /pubmed/36281159 http://dx.doi.org/10.1097/MD.0000000000031163 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | Research Article Wang, Shengnan Miao, Shijian Qiu, Xiaoxia Wu, Jie Wang, Yuhuan Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title | Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title_full | Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title_fullStr | Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title_full_unstemmed | Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title_short | Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease |
title_sort | fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known crohn’s disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592269/ https://www.ncbi.nlm.nih.gov/pubmed/36281159 http://dx.doi.org/10.1097/MD.0000000000031163 |
work_keys_str_mv | AT wangshengnan fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease AT miaoshijian fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease AT qiuxiaoxia fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease AT wujie fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease AT wangyuhuan fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease |